Keros Therapeutics, Inc. (KROS) — 8-K Filings

8-K Filings (40)

• Keros Therapeutics Files 8-K with Material Agreements and Officer Changes — Oct 15, 2025 Risk: medium
  On October 15, 2025, Keros Therapeutics, Inc. filed an 8-K report detailing several key events. These include entering into a material definitive agreement, upd
• Keros Therapeutics Files 8-K — Sep 8, 2025 Risk: low
  On September 8, 2025, Keros Therapeutics, Inc. filed an 8-K report. The filing primarily concerns other events and financial statements/exhibits, with no specif
• Keros Therapeutics Files 8-K — Aug 28, 2025 Risk: low
  Keros Therapeutics, Inc. filed an 8-K on August 28, 2025, reporting current information as required by the SEC. The filing details the company's corporate struc
• Keros Therapeutics Files 8-K — Aug 20, 2025 Risk: low
  On August 20, 2025, Keros Therapeutics, Inc. filed an 8-K report. The filing indicates that the company is a pharmaceutical preparations company incorporated in
• Keros Therapeutics Files 8-K — Jul 17, 2025 Risk: low
  Keros Therapeutics, Inc. filed an 8-K on July 17, 2025, reporting other events and financial statements. The filing details the company's corporate structure, i
• Keros Therapeutics Announces Board and Executive Changes — Jul 15, 2025 Risk: medium
  Keros Therapeutics, Inc. announced on July 9, 2025, changes related to its board of directors and executive compensation. The filing details the departure of ce
• Keros Therapeutics Files 8-K — Jun 9, 2025 Risk: low
  Keros Therapeutics, Inc. filed an 8-K on June 9, 2025, reporting on matters submitted to a vote of security holders and other events. The filing includes financ
• Keros Therapeutics Files 8-K — Jun 6, 2025 Risk: low
  Keros Therapeutics, Inc. filed an 8-K on June 6, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The filing details the compan
• Keros Therapeutics Files 8-K: Exit, Disposal, and Financials — May 29, 2025 Risk: medium
  Keros Therapeutics, Inc. filed an 8-K on May 29, 2025, reporting events as of May 28, 2025. The filing indicates information related to cost associated with exi
• Keros Therapeutics Files 8-K — May 12, 2025 Risk: low
  Keros Therapeutics, Inc. filed an 8-K on May 12, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain s
• Keros Therapeutics Files 8-K on Operations and Financials — May 6, 2025 Risk: low
  Keros Therapeutics, Inc. filed an 8-K on May 6, 2025, reporting on its results of operations and financial condition, as well as financial statements and exhibi
• Keros Therapeutics Enters Material Definitive Agreement — Apr 18, 2025 Risk: medium
  Keros Therapeutics, Inc. announced on April 17, 2025, that it has entered into a material definitive agreement. The company, focused on pharmaceutical preparati
• Keros Therapeutics Enters Material Agreement — Apr 10, 2025 Risk: medium
  Keros Therapeutics, Inc. announced on April 9, 2025, that it entered into a material definitive agreement. The company also reported material modifications to t
• Keros Therapeutics Files 8-K — Mar 31, 2025 Risk: low
  Keros Therapeutics, Inc. filed an 8-K on March 31, 2025, reporting on other events and financial statements. The filing details the company's corporate informat
• Keros Therapeutics Files 8-K for Bylaw Amendments — Mar 6, 2025 Risk: low
  Keros Therapeutics, Inc. filed an 8-K on March 5, 2025, reporting amendments to its articles of incorporation or bylaws and financial statements. The filing doe
• Keros Therapeutics Files 8-K — Feb 28, 2025 Risk: low
  Keros Therapeutics, Inc. filed an 8-K on February 28, 2025, reporting on Regulation FD disclosures and financial statements. The filing does not contain specifi
• Keros Therapeutics Files 8-K — Jan 30, 2025 Risk: low
  Keros Therapeutics, Inc. filed an 8-K on January 30, 2025, to report a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not conta
• Keros Therapeutics Files 8-K — Jan 21, 2025 Risk: low
  Keros Therapeutics, Inc. filed an 8-K on January 21, 2025, reporting an event on January 16, 2025. The filing primarily concerns financial statements and exhibi
• Keros Therapeutics Files 8-K — Jan 15, 2025 Risk: low
  Keros Therapeutics, Inc. filed an 8-K on January 15, 2025, reporting other events and financial statements. The filing does not contain specific details on new
• Keros Therapeutics Files 8-K — Jan 10, 2025 Risk: low
  Keros Therapeutics, Inc. filed an 8-K on January 10, 2025, reporting under Regulation FD and including financial statements and exhibits. The filing details the
• Keros Therapeutics Files 8-K — Dec 12, 2024 Risk: low
  Keros Therapeutics, Inc. filed an 8-K on December 12, 2024, reporting other events and financial statements. The filing does not contain specific details about
• Keros Therapeutics Files 8-K — Dec 10, 2024 Risk: medium
  Keros Therapeutics, Inc. filed an 8-K on December 10, 2024, reporting an event that occurred on December 9, 2024. The filing pertains to 'Other Events' and 'Fin
• Keros Therapeutics Files 8-K — Dec 3, 2024 Risk: medium
  On December 3, 2024, Keros Therapeutics, Inc. filed an 8-K report detailing a material definitive agreement. The filing also includes other events and financial
• Keros Therapeutics Files 8-K — Nov 26, 2024 Risk: low
  Keros Therapeutics, Inc. filed an 8-K on November 26, 2024, to report on a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not c
• Keros Therapeutics Appoints New CMO, Elects Directors — Oct 16, 2024 Risk: medium
  Keros Therapeutics, Inc. announced on October 15, 2024, the appointment of Dr. Michael R. Rickert as Chief Medical Officer and the election of Dr. Sarah L. Houg
• Keros Therapeutics Files 8-K: Other Events — Sep 30, 2024 Risk: medium
  Keros Therapeutics, Inc. filed an 8-K on September 30, 2024, reporting an event that occurred on the same date. The filing is under the 'Other Events' category,
• Keros Therapeutics Files 8-K — Sep 3, 2024 Risk: low
  Keros Therapeutics, Inc. filed an 8-K on September 3, 2024, to report other events and financial statements. The filing does not contain specific details about
• Keros Therapeutics Files 8-K — Aug 28, 2024 Risk: low
  Keros Therapeutics, Inc. filed an 8-K on August 28, 2024, to report on a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not con
• Keros Therapeutics Files 8-K — Jun 17, 2024 Risk: low
  Keros Therapeutics, Inc. filed an 8-K on June 17, 2024, to report other events and financial statements. The filing does not contain specific details about new
• Keros Therapeutics Collaborates with Bristol Myers Squibb — Jun 4, 2024 Risk: medium
  Keros Therapeutics, Inc. announced on June 4, 2024, that it has entered into a clinical trial collaboration with Bristol Myers Squibb. This collaboration will e
• Keros Therapeutics Files 8-K — Jun 3, 2024 Risk: low
  Keros Therapeutics, Inc. filed an 8-K on June 3, 2024, to report a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain s
• Keros Therapeutics Files 8-K on Security Holder Vote — May 30, 2024 Risk: low
  Keros Therapeutics, Inc. filed an 8-K on May 30, 2024, to report on the submission of matters to a vote of its security holders. The filing does not contain spe
• Keros Therapeutics Files 8-K on Executive Changes and Financials — May 28, 2024 Risk: low
  Keros Therapeutics, Inc. filed an 8-K on May 28, 2024, reporting on the departure of directors or certain officers, election of directors, appointment of certai
• Keros Therapeutics Files 8-K — Mar 14, 2024 Risk: low
  Keros Therapeutics, Inc. filed an 8-K on March 14, 2024, to report other events and financial statements. The filing does not contain specific details about new
• Keros Therapeutics Files 8-K — Mar 6, 2024 Risk: low
  Keros Therapeutics, Inc. filed an 8-K on March 6, 2024, to report on a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not conta
• Keros Therapeutics Appoints New Chief Medical Officer — Mar 5, 2024 Risk: medium
  Keros Therapeutics, Inc. announced on February 29, 2024, the appointment of Dr. Michael R. Rick as Chief Medical Officer and Dr. Jessica L. Smith as Chief Devel
• Keros Therapeutics Files 8-K on Financial Condition — Feb 28, 2024 Risk: medium
  Keros Therapeutics, Inc. filed an 8-K on February 28, 2024, reporting on its results of operations and financial condition. The filing indicates that the compan
• Keros Therapeutics Files Routine 8-K for Other Event, Exhibits — Jan 9, 2024
  Keros Therapeutics, Inc. filed an 8-K on January 9, 2024, to report an "Other Event" and provide "Financial Statements and Exhibits." This filing indicates a ro
• Keros Therapeutics Files Routine 8-K on Jan 3 Event — Jan 4, 2024
  Keros Therapeutics, Inc. filed an 8-K on January 4, 2024, reporting an event that occurred on January 3, 2024. This filing is a routine disclosure under 'Other
• Keros Therapeutics Files Routine 8-K on Jan 3, 2024 — Jan 3, 2024
  Keros Therapeutics, Inc. filed an 8-K on January 3, 2024, primarily to disclose information under Regulation FD and other events. This filing indicates that Ker

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX